Capital Insights
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
A new Perth-based gold and copper focused exploration company has announced plans to raise up to $6 million by way of an initial public offering and list on the ASX.
KEY TAKEAWAYS:
“The company has already commenced exploration activities, including a high-resolution aeromagnetic survey over much of the company’s Bryah Basin project area, which was completed in early April,” Mr Crow said in Bryah’s prospectus.
“This aeromagnetic survey will provide additional funds to advance exploration on the company’s projects developed to commence following the successful listing of Bryah on the ASX.”
Request Offer